Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by Pier Capital LLC

Pier Capital LLC reduced its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 1.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 422,730 shares of the company’s stock after selling 7,178 shares during the quarter. Pier Capital LLC owned about 0.06% of Roivant Sciences worth $5,001,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its holdings in shares of Roivant Sciences by 57.0% during the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after buying an additional 1,288 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Roivant Sciences by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock worth $84,000 after acquiring an additional 1,507 shares during the last quarter. Quarry LP grew its stake in Roivant Sciences by 50.0% during the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $87,000 after acquiring an additional 2,500 shares in the last quarter. Blue Trust Inc. raised its holdings in Roivant Sciences by 550.1% in the 4th quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock valued at $91,000 after acquiring an additional 6,667 shares during the last quarter. Finally, HighTower Advisors LLC purchased a new position in Roivant Sciences in the 4th quarter worth approximately $121,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on ROIV shares. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a research report on Tuesday, February 11th. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $18.08.

Insider Buying and Selling at Roivant Sciences

In other news, Director Sciences Ltd. Roivant bought 16,845,010 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The shares were purchased at an average price of $20.00 per share, with a total value of $336,900,200.00. Following the purchase, the director now owns 96,650,341 shares in the company, valued at approximately $1,933,006,820. The trade was a 21.11 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Eric Venker sold 176,900 shares of the firm’s stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $11.82, for a total value of $2,090,958.00. Following the transaction, the chief operating officer now owns 668,680 shares of the company’s stock, valued at $7,903,797.60. This trade represents a 20.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,439,640 shares of company stock worth $27,451,035 over the last three months. Insiders own 7.90% of the company’s stock.

Roivant Sciences Stock Performance

Shares of Roivant Sciences stock opened at $10.83 on Tuesday. The stock has a 50 day moving average of $10.79 and a 200 day moving average of $11.45. The firm has a market capitalization of $7.73 billion, a price-to-earnings ratio of -72.20 and a beta of 1.26. Roivant Sciences Ltd. has a fifty-two week low of $9.93 and a fifty-two week high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Analysts forecast that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.